Optinose Q3 2022 Earnings Report
Key Takeaways
Optinose reported Q3 2022 XHANCE net revenue of $20.1 million. The company anticipates submitting an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023. They expect full year 2022 XHANCE net revenue to be between $74 to $78 million and full year 2022 operating expenses to be between $127 to $131 million.
XHANCE net revenue for Q3 2022 was $20.1 million, a decrease of 8% compared to Q3 2021.
The company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023.
Full year 2022 XHANCE net revenue is expected to be between $74 to $78 million.
Full year 2022 operating expenses are expected to be between $127 to $131 million; full year 2023 operating expenses expected to decrease materially.
Optinose
Optinose
Forward Guidance
Optinose expects XHANCE net revenues for the full year of 2022 to be between $74 to $78 million and full year 2022 XHANCE average net revenue per prescription to be approximately $220. The company expects total GAAP operating expenses for 2022 to be in the range of $127 - $131 million. They also expect total GAAP operating expenses for full year 2023 to decrease materially compared to full year 2022 total GAAP operating expenses.